A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of
 moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal
 women. The primary study hypothesis is that one or more doses of MK-6913 will result in a
 significantly greater reduction from baseline, compared to placebo, in the number of moderate
 to very severe hot flashes after 4 weeks of treatment.
Inclusion Criteria:

 -  Woman with at least 50 moderate to very severe hot flash episodes per week

 -  Postmenopausal

 -  Between 45 and 60 years of age if naturally menopausal, or between 35 and 60 if she
 underwent a bilateral oophorectomy

 -  Not receiving hormone therapy

 -  Has had both a normal mammogram and a normal Pap test in the past 6 months

 -  Generally healthy

 Exclusion Criteria:

 -  A history of cancer, except for certain skin cancers

 -  Undiagnosed vaginal bleeding or any uterine endometrial disorder

 -  Currently uses tobacco products, or has used them in the last 6 months

 -  Has human immunodeficiency virus (HIV)